| 09/04/24 | 16:00:46 | 9 Apr 2024 | | Issue of RiverFort Subscription Shares | RNS |
| 04/04/24 | 14:38:22 | 4 Apr 2024 | | Completion of Equity Fundraise | RNS |
| 02/04/24 | 16:51:15 | 2 Apr 2024 | | Result of WRAP Retail Offer | RNS |
| 02/04/24 | 07:00:13 | 2 Apr 2024 | | Increase in size of WRAP Retail Offer | RNS |
| 28/03/24 | 07:02:00 | 28 Mar 2024 | | WRAP Retail Offer | RNS |
| 28/03/24 | 07:01:00 | 28 Mar 2024 | | Equity Fundraise | RNS |
| 28/03/24 | 07:00:14 | 28 Mar 2024 | | Sareum Half-Year Report | RNS |
| 15/03/24 | 07:00:06 | 15 Mar 2024 | | New Patent Allowance | RNS |
| 12/03/24 | 13:30:00 | 12 Mar 2024 | | Notice of Interim Results and Trading Update | RNS |
| 15/02/24 | 07:00:02 | 15 Feb 2024 | | Update on SDC-1801 Clinical Trial Progress | RNS |
| 02/01/24 | 07:00:05 | 2 Jan 2024 | | Development and commercialisation licence SRA737 | RNS |
| 14/12/23 | 15:35:33 | 14 Dec 2023 | | Results of AGM | RNS |
| 14/12/23 | 07:00:15 | 14 Dec 2023 | | Annual General Meeting Statement | RNS |
| 23/11/23 | 07:00:07 | 23 Nov 2023 | | Drawdown of Equity Prepayment Facility | RNS |
| 21/11/23 | 07:00:13 | 21 Nov 2023 | | Notice of AGM, Annual Report and Accounts | RNS |
| 09/11/23 | 07:00:11 | 9 Nov 2023 | | Initiation of food effects study for SDC-1801 | RNS |
| 08/11/23 | 15:03:54 | 8 Nov 2023 | | Director Dealings | RNS |
| 03/11/23 | 07:05:45 | 3 Nov 2023 | | Sareum enhances SDC-1801 patent protection | RNS |
| 02/11/23 | 14:48:18 | 2 Nov 2023 | | Exercise of Share Options and Director Dealings | RNS |
| 09/10/23 | 07:00:10 | 9 Oct 2023 | | Final Results for the Year Ended 30 June 2023 | RNS |
| 03/10/23 | 07:00:05 | 3 Oct 2023 | | Notice of Results and Investor Presentation | RNS |
| 06/09/23 | 07:00:06 | 6 Sept 2023 | | Director's Dealing | RNS |
| 05/09/23 | 07:00:06 | 5 Sept 2023 | | Director Dealing | RNS |
| 04/09/23 | 07:00:03 | 4 Sept 2023 | | Dosing of first subjects in MAD Phase 1a trial | RNS |
| 16/08/23 | 07:00:04 | 16 Aug 2023 | | Update on financial and operational progress | RNS |
| 03/08/23 | 07:00:09 | 3 Aug 2023 | | Equity Prepayment Facility of up to £5 million | RNS |
| 26/06/23 | 07:00:02 | 26 Jun 2023 | | Sareum Announces Two New Granted Patents | RNS |
| 06/06/23 | 07:00:07 | 6 Jun 2023 | | Dosing commences in Phase 1a trial of SDC-801 | RNS |
| 18/05/23 | 07:00:34 | 18 May 2023 | | Phase 1a clinical trial for SDC-1801 | RNS |
| 05/05/23 | 09:20:15 | 5 May 2023 | | Approval to initiate Phase 1 clinical trial | RNS |
| 22/03/23 | 07:00:04 | 22 Mar 2023 | | Half-Year Report | RNS |
| 15/03/23 | 07:01:01 | 15 Mar 2023 | | Update on SDC-1801 | RNS |
| 15/03/23 | 07:00:10 | 15 Mar 2023 | | Notice of Half-Year Results | RNS |
| 06/03/23 | 07:00:02 | 6 Mar 2023 | | Update on SRA737 | RNS |
| 29/12/22 | 15:14:26 | 29 Dec 2022 | | Director/PDMR Shareholding | RNS |
| 16/12/22 | 15:29:18 | 16 Dec 2022 | | Results of AGM | RNS |
| 16/12/22 | 07:00:03 | 16 Dec 2022 | | AGM Statement | RNS |
| 24/11/22 | 07:00:05 | 24 Nov 2022 | | Notice of AGM, Annual Report and Accounts | RNS |
| 21/11/22 | 07:00:10 | 21 Nov 2022 | | Sareum notes publication of SRA737 clinical data | RNS |
| 09/11/22 | 16:41:38 | 9 Nov 2022 | | Second Price Monitoring Extn | RNS |
| 09/11/22 | 16:35:59 | 9 Nov 2022 | | Price Monitoring Extension | RNS |
| 09/11/22 | 14:05:58 | 9 Nov 2022 | | Second Price Monitoring Extn | RNS |
| 09/11/22 | 14:00:36 | 9 Nov 2022 | | Price Monitoring Extension | RNS |
| 09/11/22 | 11:05:46 | 9 Nov 2022 | | Second Price Monitoring Extn | RNS |
| 09/11/22 | 11:00:27 | 9 Nov 2022 | | Price Monitoring Extension | RNS |
| 09/11/22 | 09:05:56 | 9 Nov 2022 | | Second Price Monitoring Extn | RNS |
| 09/11/22 | 09:00:25 | 9 Nov 2022 | | Price Monitoring Extension | RNS |
| 08/11/22 | 17:23:12 | 8 Nov 2022 | | Update on SDC-1801 CTA Application | RNS |
| 24/10/22 | 07:00:09 | 24 Oct 2022 | | Final Results for the Year Ended 30 June 2022 | RNS |
| 12/10/22 | 07:00:05 | 12 Oct 2022 | | Update on SRA737 | RNS |
